# NCT05382559 (NCT05382559)

> A Study of ASP3082 in Adults With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05382559
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Astellas Pharma Inc
- Conditions: Solid Tumor
- Interventions: Setidegrasib; Cetuximab; Leucovorin; Oxaliplatin; Fluorouracil; Irinotecan; Nanoparticle albumin-bound-paclitaxel; Gemcitabine; Docetaxel; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; Liposomal Irinotecan
- Enrollment: 681
- Primary outcome: Incidence of Dose Limiting Toxicities (DLTs)
- Primary outcome: Number of Participants with Adverse Events (AEs)
- Primary outcome: Number of Participants with Serious Adverse Events (SAEs)
- Primary outcome: Number of Participants with laboratory value abnormalities and/or adverse events (AEs)
- Primary outcome: Number of Participants with electrocardiogram (ECG) abnormalities and/or adverse events (AEs)
- Primary outcome: Number of Participants with vital sign abnormalities and/or adverse events (AEs)
- Primary outcome: Number of Participants with physical exam abnormalities and/or adverse events
- Primary outcome: Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05382559